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Abstract
Introduction: Simvastatin and diltiazem are often prescribed together for the
treatment of hypercholesterolaemia in patients with hypertension and/or angina
pectoris. However, diltiazem, a CYP3A inhibitor, is a well-recognized risk factor
of skeletal muscle myopathy. It is not known whether such interaction also
affects myocardial efficiency causing haemodynamic changes. The aim of the
experiment was to establish the impact of simvastatin co-administered with
diltiazem on the haemodynamic parameters after continuous infusion of
dopamine. 
Material and methods: The experiments were performed on 28 New Zealand
white rabbits. The animals were divided into four groups receiving: 0.2% MC –
methylcellulose (control group); diltiazem; simvastatin; simvastatin + diltiazem,
for 14 days (po). The following haemodynamic parameters were estimated:
cardiac output index (CI), heart rate (HR), systolic blood pressure (SBP), mean
blood pressure (MBP), diastolic blood pressure (DBP) and total peripheral
resistance index (TPRI). The registration of haemodynamic parameters was
performed by the Doppler method and during the experiments the animals were
anaesthetized with α-chloralose (75 mg/kg bw) and urethane (500 mg/kg bw).
Results: Dopamine did not cause a statistically significant increase in CI in rabbits
receiving simvastatin alone. Diltiazem significantly increased CI if given
simultaneously with simvastatin, which might suggest the improvement of
cardiac efficiency resulting from such interaction.
Conclusions: The possibility of another mechanism of drug-drug interaction than
the one based on CYP3A inhibition, and its impact on cardiac or skeletal muscle,
might be considered.
Key words: statins, diltiazem, haemodynamic parameters, myopathy, myocardium,
rabbits. 
Introduction
3-hydroxy-3-methyl-glytaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins, HMGRI) have been proven to be extremely useful in the
management of hypercholesterolaemia, especially with an elevated low-
density lipoprotein cholesterol (LDL-C) level. Due to their pleiotropic
activities, the long-term efficacy of statins for the primary and secondary
[1-4] prevention of coronary heart disease is also well established. Until
recently, the clinical trials have been performed to support the benefit of
these agents for acute coronary syndromes [5].
Statins are well tolerated by most patients, but may produce a variety of
muscle-related symptoms such as myopathy and rhabdomyolysis, accounting
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for 2% to 5% of all musculoskeletal effects. However,
still little is known as to how statins produce muscle
injury [6, 7]. It has been shown that statin-related
myotoxicity followed a dose-response curve. Thus,
it is more likely to occur with higher serum statin
concentrations. It may increase significantly when
HMGRIs, including simvastatin, metabolized by the
CYP3A isoenzyme, are prescribed concomitantly with
other drugs inhibiting their metabolism via the CYP3A
pathway (e.g. antifungal and immunosuppressive
drugs, and macrolides). Co-administration of sim  -
vastatin and diltiazem or mibefradil has also been
proven to increase the circulating simvastatin
concentration [8-10]. 
Diltiazem, a calcium channel blocker (CCB), is
a well-established anti-ischaemic agent, used
especially in vasospastic angina pectoris (Guidelines
on the Management of Stable Angina Pectoris), and
quite frequently there is a need for its combined
administration with statin. Simvastatin and diltiazem
are often prescribed together for the treatment of
hypercholesterolaemia in patients with hypertension
and/or angina pectoris, and in such cases caution
is recommended due to the risk of development of
well-known musculoskeletal adverse effects.
Moreover, in some cases the guidelines recommend
such combination if the clinical benefit is likely to
outweigh the increased risk of myopathy and
rhabdomyolysis [11, 12]. There is little evidence as to
whether such interaction similarly to skeletal muscle
also affects cardiac muscle. Thus, taking into
consideration the clinical importance of interactions
resulting from the co-administration of CCBs and
HMGRIs, the haemodynamic estimation of cardiac
function, especially its efficiency, was planned. As
a function of myocardial efficiency, one of its
parameters – cardiac output resulting from
a continuous infusion of a positive inotropic agent,
dopamine – was assessed. 
Material and methods
Drugs: simvastatin (Polfarmex, Poland series no.
KY-SI-M20030102), diltiazem (Diltiazemi hydro  -
chloridum, Polfarmex, Poland, series no. 010203),
dopamine (Dopaminum hydrochloricum 1%, Polfa
Warszawa, Poland, series no. 01AV0203), α-chlo  -
ralose (Sigma, USA, series no. 120K2505), urethane
(Sigma, USA, series no. 022K1248), lidocaine
(Lidocaini hydrochloridum 2%, Polfa Warszawa,
Poland, series no. 14BT0403), methylcellulose 
(Fluka, Switzerland, series no RB 13425), natrium
chloratum 0.9% inj. (Polfa Lublin, Poland, series 
no. 10602). 
The experiments were performed on 28 outbred
New Zealand white rabbits, both sexes, body weight
2.7-4.5 kg, fed on granulated mix LSK with free
access to water. The animals were housed in stan  -
dard cages, one animal per cage. The expe  rimental
procedures were carried out in accordance with the
international guidelines for care and use of
laboratory animals. All efforts were made to
minimize animal suffering and reduce the number
of animals used in the experiments. All the
procedures in these experiments were approved by
the Ethics Committee of the Medical University of
Lodz, Poland (Ł/BD/131). 
The animals were divided into four groups of
rabbits, randomly allocated to each group:
group I: 0.2% methylcellulose (MC), 1 ml/kg bw, 
po daily for 14 days (n = 9);
group II: diltiazem 5 mg/kg bw, po daily for 14 days
(n = 6);
group III: simvastatin 50 mg/kg bw, po daily for 
14 days (n = 6);
group IV: simvastatin 50 mg/kg bw + diltiazem 
5 mg/kg bw, po daily for 14 days (n = 7).
All drugs, in doses used in the previous
experiments in rabbits [13, 14], were administered
by oral gavage, suspended in 0.2% MC. 
Haemodynamic studies
The surgery was performed 24 h after the
administration of the last drug dose. The rabbits were
placed in a dorsal position on the operation table.
The animals were anaesthetized with α-chloralose
(75 mg/kg bw) and urethane (500 mg/kg bw),
administered into the marginal ear vein.
Anaesthesia was maintained by additional bolus
doses of urethane as needed. Lidocaine was used
for local infiltration of the surgical sites. During the
experimental procedures, the thoracic cavity was
opened for further aortic flow measurement from
the ascending aorta. Before thoracotomy, the
trachea was intubated. Ventilator frequency was
set at 30 bpm and tidal volume at 10 ml/kg bw. 
Dopamine, dissolved in 0.9% NaCl, was infused
into the marginal ear vein, using a continuous
infusion pump (sp100i syringe pump, WPI, England),
at 10 μg/kg min bw. The infusion was begun after
the stabilization period.
The registration of haemodynamic parameters
in rabbits was performed using Hugo Sachs
Electronik Haemodyn (Harvard Apparatus GmbH,
March, Germany).
For the measurement of systolic, mean and
diastolic arterial blood pressure (systolic blood
pressure – SBP, mean blood pressure – MBP,
diastolic blood pressure – DBP), a heparinized
polyethylene catheter was placed into the dissected
carotid artery and connected to an Isotec pressure
transducer (HSE Harvard Apparatus, Germany).
After median sternotomy and pericardiotomy, an
ultrasonic flow probe was placed around the
ascending aorta and connected to an ultrasonic
flow meter Transit Time Flowmeter TTFM Type 700
(HSE Harvard Apparatus and Transonic System Inc.390 Arch Med Sci 3, June / 2011
USA), in order to measure aortic blood flow 
(AFmax, AFmean, AFmin). The AFmean values were taken
as an index of cardiac output. The heart rate 
was registered from the catheter placed in the
carotid artery. After surgery, the animals were 
killed by exsanguination while ventilation was
continued.
All analogue signals were amplified and recorded
on a computer via an A/D converter (HSE Haemodyn
software for Microsoft Windows 95/98/NT) and
evaluated according to the algorithms. For further
statistical analysis, the mean from 3-minute periods
was calculated as output values. 
The following derivative haemodynamic
parameters were calculated: cardiac output index
(CI) and total peripheral resistance index (TPRI):
– CI = CO/BW (ml/min kg), CO – cardiac output
(ml/min), BW – body weight (kg);
–  TPRI = TPR/BW (mmHg min/ml kg), TPR =
MAP/CO (mmHg min/ml), MAP – mean arterial
pressure (mmHg).
Statistic analysis 
The statistical analysis of haemodynamic
parameters was carried out using the Statistica
version 5.0 StatSoft program. The statistical
evaluation was performed using the analysis of
variance (ANOVA) and post-hoc comparisons were
performed using the Duncan test. Normal distri  -
bution of a parameter was checked by means of
the Kolmogorov-Smirnov test with the Lilliefors
correction. The homogeneity of variance was tested
by Levene's test. If data were not normally distri  bu  -
ted or the values of variance were different, ANOVA
with the Kruskal-Wallis and Mann-Whitney U test
was used.
All parameters were considered statistically
significantly different if p < 0.05.
Results 
Haemodynamic studies
Cardiac output index 
In the control group, the dopamine infusion
caused a statistically significant increase in CI,
observed from the 15th min to the end of the
experiment, maximally by 19%. In rabbits receiving
diltiazem, a significant increase in CI was observed
from the 9th min to the end of the experiment,
maximally by 37%. The administration of sim  vas  -
tatin alone did not result in a statistically significant
increase in CI during the continuous infusion of
dopamine. In rabbits receiving simvastatin
simultaneously with diltiazem, the continuous
infusion of dopamine caused a statistically
significant increase in CI values, maximally by 23%,
observed from the 6th min after the infusion had
been started (Figure 1).
The initial values of CI noted in rabbits receiving
simvastatin or diltiazem did not differ significantly
from the values of CI noted in the control group
(Figure 1).
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Figure 1. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on cardiac output index (CI) in rabbits, during continuous infusion of dopamine, given simultaneously.
Each value represents the mean ± SEM. (a) p < 0.05 in comparison to diltiazem alone, (b) p < 0.05, (c) p < 0.01, 
(d) p < 0.005 in comparison to simvastatin alone, in comparison to diltiazem alone: (*) p < 0.05, (§)p < 0.005 in
comparison to the initial values (0'). 0' – the initiation of dopamine infusion
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The combined administration of simvastatin
with diltiazem caused a marked increase in the
cardiac output index, observed from the 6th min of
the dopamine infusion as compared to simvastatin
alone (Figure 1). 
Blood pressure 
Dopamine infusion did not influence systolic
blood pressure values in the examined groups of
rabbits. The values of SBP and MBP, observed after
dopamine infusion had been started, did not differ
significantly from the initial values. 
The values of SBP observed in rabbits receiving
diltiazem or simvastatin alone were significantly
lower as compared to the control group. The
combined administration of simvastatin and
diltiazem caused a marked decrease in the values
of SBP compared to the control group, both before
and during the dopamine infusion (Figure 2). 
In the control group, as well as in rabbits
receiving diltiazem alone or simultaneously with
simvastatin, dopamine did not cause any changes
in MBP values. The simultaneous administration of
simvastatin and diltiazem caused a marked
decrease in MBP values, compared to the control
group (Figure 3). 
An insignificant influence of dopamine on DBP
values was observed, except for the last 18 min in
rabbits receiving simvastatin alone. 
The values of DBP observed in rabbits receiving
diltiazem were significantly lower as compared to
the control group. The combined administration of
simvastatin with diltiazem resulted in DBP
reduction compared to the control group (Figure 4).
Heart rate 
The administration of dopamine caused
a marked reduction of the heart rate (HR) values in
groups receiving simvastatin alone, observed from
the 9th min of dopamine infusion to the end of the
experiment. In rabbits receiving simvastatin with
diltiazem, dopamine significantly slowed the
rabbits’ heart rate beginning from the 12th min of
its administration to the end of the experiment.
The administration of simvastatin alone or with
diltiazem resulted in a decrease in HR, compared to
the control group. These changes were statistically
significant after the dopamine infusion had started.
In rabbits receiving simvastatin simultaneously with
diltiazem, a marked decrease in HR compared to
diltiazem alone was noted. These changes were
statistically significant, beginning from the 18th min
of the dopamine infusion (Figure 5). 
Total peripheral resistance index 
The infusion of dopamine caused a reduction in
TPRI in the examined groups of rabbits. A significant
decrease in TPRI in rabbits receiving diltiazem with
simvastatin was observed after the 3rd min of
dopamine infusion. In the group receiving
simvastatin alone, a marked reduction in TPRI was
noted after the 30th min of dopamine adminis  -
tration. In the control group, a significant decrease
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Figure 2. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on systolic blood pressure (SBP) in rabbits, during continuous infusion of dopamine, given simultaneously.
Each value represents the mean ± SEM. (a) p < 0.05 in comparison to the control group. 0' – the initiation of dopamine
infusion
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in TPRI was observed after the 27th min of dopa  -
mine administration (Figure 6).
Discussion
Diltiazem is a recognized risk factor of statin-
induced myopathy of skeletal muscles. As a substrate
and inhibitor of the human liver microsomal enzyme
CYP3A, by which simvastatin is also metabolized,
diltiazem significantly increases the mean peak
serum concentration of simvastatin (by 3.6-fold) as
well as the area under the serum concentration-time
curve (by 5-fold) [15]. Pharmacokinetic interaction
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Figure 3. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on mean blood pressure (MBP) in rabbits, during continuous infusion of dopamine, given simultaneously.
Each value represents the mean ± SEM. (a) p < 0.05 in comparison to the control group, (*) p < 0.05 in comparison
to the initial values (0'). 0' – the initiation of dopamine infusion
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Figure 4. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on diastolic blood pressure (DBP) in rabbits, during continuous infusion of dopamine, given simultaneously.
Each value represents the mean ± SEM. (a) p < 0.05 in comparison to the control group, (*) p < 0.05 in comparison
to the initial values (0'). 0' – the initiation of dopamine infusion
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between statin and diltiazem is known to enhance
the pharma  codynamic effect of simvastatin and may
lead to an increased risk of statin side effects,
including myopathic symptoms. On the other hand,
the magnitude of this interaction is smaller than
observed with other CYP3A inhibitors such as
itraconazole or mibefradil, a selective T-type calcium
channel blocker inhibitor. Myopathy occurs in about
1% of patients taking simvastatin in higher doses
with verapamil or with diltiazem, and considering the
risk of such adverse musculoskeletal symptoms
caution is recommended [16]. 
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Figure 5. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on heart rate (HR) in rabbits, during continuous infusion of dopamine, given simultaneously. Each value
represents the mean ± SEM. (a) p < 0.05 in comparison to diltiazem alone, (b) p < 0.05, (c) p < 0.005 in comparison
to the control group, (*) p < 0.05 in comparison to the initial values (0'). 0' – the initiation of dopamine infusion
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Figure 6. The influence of diltiazem ( ), simvastatin (), diltiazem + simvastatin (×), in comparison to the control
group ( ), on total peripheral resistance index (TPRI) in rabbits, during continuous infusion of dopamine, given
simultaneously. Each value represents the mean ± SEM. (*) p < 0.05 in comparison to the initial values (0'). 0' – the
initiation of dopamine infusion
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Our findings indicate that diltiazem may improve
cardiac efficacy in terms of statin administration.
The simultaneous administration of simvastatin
with diltiazem resulted in an increase in CI. The
administration of simvastatin alone did not cause
a significant reduction in the initial CI values (i.e.
before dopamine infusion); no response to
dopamine inotropic activity was observed as
opposed to the other groups. In contrast, we have
shown that nifedipine significantly worsened the
cardiac function if given simultaneously with
simvastatin, suggesting that nifedipine may have
a detrimental impact on statin therapy [17].
Diltiazem, but not nifedipine however, by inhibition
of smooth muscle L-type calcium channels,
decreases intracellular calcium concentration not
only in smooth muscle cells but also in
cardiomyocytes. 
Calcium overload is one of the suggested factors
responsible for skeletal muscle myopathy
development. Nakahara et al. (1994) revealed that
simvastatin and simvastatin acid elevated Ca2+ in
L6 rat myoblasts [18]. Similarly, intracellular Ca2+
increase in cardiomyocytes was reported as well. If
statin-induced Ca2+ elevation plays a role in
development of myotoxicity, this could explain why
concomitant administration of diltiazem and
simvastatin improves cardiac efficiency compared
to simvastatin alone. It is already known that
diltiazem by inhibiting Ca2+ inflow to the ischaemic
myocardium and preventing mitochondrial damage
may have a positive influence on the performance
of the damaged cardiac muscle, including diastolic
dysfunction [19]. The cardioprotective properties of
diltiazem were confirmed in another study by Wang
et al. The authors suggested that diltiazem might
restore cardiac output and improve renal function
after haemorrhagic shock and crystalloid resus  -
citation [20].
The reduction of heart rate after simvastatin
administration seems to be controversial
considering its impact on Ca2+ uptake in cardio  -
myocytes. However, some findings have indicated
the sympathoinhibitory effects of statins [21]. The
possible molecular mechanism might involve statin-
induced reduction in the production of several
important isoprenoids such as farnesyl pyro  -
phosphate (FPP) and geranylgeranyl pyro  phosphate
(GGPP). Very recent studies have shown that statins
could increase extracellular adenosine formation
from adenosine mono  phosphate by enhancing
ecto-5’-nucleotidase activity, which may result in
decrease of the heart rate [22]. 
In the performed experiment, diltiazem
significantly reduced SBP and MBP values as
compared to the control group. This confirms its
antihypertensive properties in the examined rabbit
model and results from the direct relaxing efficacy
of diltiazem associated with inhibition of the
smooth muscle L-type calcium channel. In our study,
simvastatin administration caused a statistically
significant decrease in SBP compared to the control
group. Some clinical studies have shown beneficial
effects of statins on BP . The possible mechanisms
responsible for the above effects have been
discussed widely (Jasińska et al. 2007) and may
involve an increase in NO production or a decrease
in AT1 expression [23-25]. However, the BP-lowering
effects of statins are observed mainly in
hypertensive patients. Despite this fact, we suggest
that the high dose of simvastatin used in our
experiment might have an impact on the obtained
results also in normolipidaemic and normotensive
rabbits. The values of BP in rabbits receiving
simvastatin and diltiazem alone or concomitantly
remained at the same level. Conversely, the previous
studies showed that simultaneous administration
of simvastatin and another CCB, nifedipine, caused
a significant decrease in BP values as compared to
rabbits receiving nifedipine alone [17]. We suggested
a mechanism based on pharmacokinetic drug-drug
interaction: the suppression of nifedipine
metabolism by simvastatin, resulting from com  -
petition of both drugs for CYP3A. In the present
study, a further decrease in BP values after the
concomitant administration of simvastatin and
diltiazem was not observed. Unfortunately, due to
lack of suitable equipment, in the present
experiment, we were not able to measure the
serum concentration of CCB to confirm the
hypothesis of the pharmacokinetic drug-drug
interaction at the level of isoenzyme CYP3A. 
Dopamine caused a further marked reduction in
TPRI in the examined groups of rabbits. Systemic
and peripheral vascular resistance reduction
resulting from dopamine administration is a con  -
sequence of D1 and D2 receptor stimulation [26]. 
The limitation of the extrapolation of our data
to humans is the relatively high dose of simvastatin
used in our experiments. However, the aim of the
present study was to assess whether simvastatin
co-administered with CYP3A inhibitor, in a dose
provoking myopathy of skeletal muscles, influences
myocardium efficiency. On the other hand, a much
bigger role has been assigned to the aggressive
lowering of LDL-C, which is connected with higher
doses of hypolipaemic drugs, especially statins. As
we have mentioned above, the literature findings
indicated the small percentage of statin-induced
musculoskeletal adverse effects (2-5%). Thus, the
number of animals used in this experiment might
be insufficient. However, a high dose of simvastatin
(50 mg/kg) administered to animals seems to
increase the likelihood of myotoxicity incidence. 
It has been suggested that changes of
haemodynamic parameters might be the con  -
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sequence of interaction at the isoenzyme CYP3A
level. Previous findings have confirmed the
functional similarity of intestinal CYP3A forms in
rabbits and humans, suggesting that the rabbit is
a beneficial in vivo model for the assessment of
drug interaction occurring at the first pass of drugs
ingested. Moreover, studies performed on rabbits,
evaluating the pharmacokinetics of other drugs
metabolized in humans via the CYP3A pathway (i.e.
diltiazem, saquinavir) [27], have confirmed the
usefulness of the rabbit model for such inves  -
tigations.
In conclusion, the role of HMGRIs in the primary
and secondary prevention of ischaemic heart
disease is well established. However, the me  -
chanism of the highest possible statin affinity to
the skeletal muscle in comparison to the cardiac
muscle in the development of HMGRI myotoxicity
has not been determined. In the performed study,
the concomitant administration of diltiazem,
a CYP3A inhibitor, with statin surprisingly resulted
in an increase of CI, which might suggest improved
cardiac efficiency resulting from such interaction.
We hypothesize that the impact of diltiazem co-
administered with simvastatin on myocardium
might be the consequence of both CYP3A inhibition
and the beneficial influence on calcium signaling.
Additionally, lack of diltiazem affinity to L-type
calcium channels in myocytes may elucidate
a greater risk of skeletal muscle toxicity after
simvastatin and diltiazem compared to myo  -
cardium.
Changes noted in other haemodynamic
parameters (BP, HR, TPRI) may throw some light on
the complex impact of statin administration on
cardiovascular performance, the variety of me  cha  -
nisms still remaining questionable.
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